Plasma for Fractionation

Production of Plasma Proteins for Therapeutic Use

Volumn , Issue , 2012, Pages 423-436

  Bertolini, Joseph ^a   Hayes, Timothy ^b  

^a CSL Biotherapies   (Australia)

^b TKH Bioconsult LLC   (United States)

Author keywords

GMP, in plasma collection; Plasma for fractionation; Plasma in transfusion manufacture; Plasma, specific clinical use; US FDA, and NAT

Indexed keywords

EID: 84886143936     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118356807.ch31     Document Type: Chapter

References (45)

1. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth NJ, Melin M, Taylor HL. (1946) Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc, 68, 459-475.
2. Turner PJ, Young IF, Marley PB, Herrington RW, Schiff P. (1987) Albumin solutions-their production and quality control. Dev Biol Stand, 67, 119-127.
3. Lebing W, Remington KM, Schreiner C, Paul HI. (2003) Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang, 84, 193-201.
4. Burnouf T, Radosevich M. (2001) Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods, 49, 575-586.
5. United States Food and Drug Administration, Code of Federal Regulations Title 21 Parts 600 to 799, Food and Drugs www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Accessed February 2, 2012.
6. Kakaiya R, Aronson CA, Julleis J. (2008) Whole blood collection and component processing. In: Technical manual, 16th edition (Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds.). American Association of Blood Banks, Maryland, USA, pp. 189-228.
7. Smith JW, Burgstaler EA. (2008) Blood component collection by apharesis. In: Technical manual, 16th Edition (Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds.). American Association of Blood Banks, Maryland, USA, pp. 229-239.
8. Guide to the preparation, use and quality assurance of blood components (16th Edition)-recommendation R (95) 15 (2011) Plasma components. Directorate for the Quality of Medicines and Healthcare, Strasbourg, France. pp. 311-325.
9. European Pharmacopoeia (7th Edition) (2011) Human plasma for fractionation. Directorate for the quality of medicines and healthcare, Strasbourg, France.
10. United States Food and Drug Administration. (2011) Current considerations on plasma for further manufacturing obtained from whole blood donors. Blood Products Advisory Committee Meeting, April 2011. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/bloodproductsadvisorycommittee/ucm251511.pdf. Accessed February 8, 2012.
11. Plasma Protein Therapeutics Association. Programs and Standards. www.pptaglobal.org/program/default.aspx. Accessed February 8, 2012.
12. Eder AF. (2008) Allogeneic and autologous blood donor selection. In: Technical manual, 16th Edition (Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds.). American Association of Blood Banks, Maryland, USA, pp. 137-187.
13. American Association of Blood Banks. (2011) Standards for blood banks and transfusion services, 27th Edition. American Association of Blood Banks, Maryland, USA pp. 10-31.
14. United States Food and Drug Administration. Keeping Blood Transfusions Safe: FDA's Multi-layered Protections for Donated Blood. www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/ucm095522.htm. Accessed February 8, 2011,
15. Fiebig EW, Busch MP. (2008) Infectious disease screening. In: Technical manual, 16th Edition (Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds.). American Association of Blood Banks, Maryland, USA, pp. 241-282.
16. Wang B, Schreiber GB, Glynn SA, Nass CC, Smith JW, Higgins MJ, Hutching ST, Wright DJ, McEntire RL, Murphy EL, Retrovirus Epidemiology Donor Study. (2003) Prevalence of transfusion-transmissible viral infections in first-time US blood donors by donation site. Transfusion, 43, 705-712.
17. Plasma Protein Therapeutics Association. International quality plasma program standard for viral markers. www.pptaglobal.org/UserFiles/file/QSEAL/Viral%20Marker%20Standard_v4.1January%202009.pdf. Accessed February 8, 20 12.
18. Plasma Protein Therapeutics Association. National Donor Deferral Registry (NDDR). www.pptaglobal.org/program/deferral.aspx. Accessed February 8, 2012.
19. Plasma Protein Therapeutics Association. International Quality Plasma Program (IQPP). www.pptaglobal.org/program/ iqpp.aspx. Accessed February 8, 2012.
20. Plasma Protein Therapeutics Association. International quality plasma program for qualified donors. www.pptaglobal. org/program/Qualified_Donor_Standard_v3-0.pdf. Accessed February 8, 2012.
21. Plasma Protein Therapeutics Association. International quality plasma program for community-based donors. www.pptaglobal.org/UserFiles/File/QSEAL/Community-based%20StandardV3.0_January%202009.pdf. Accessed February 8 , 2012 .
22. Plasma Protein Therapeutics Association. International quality plasma program for donor education. www.pptaglobal.org/UserFiles/File/QSEAL/DonorEducation_V2.0_January%202009.pdf. Accessed F ebrua ry 8 , 20 12.
23. Plasma Protein Therapeutics Association. Quality Standards of Excellence, Assurance and Leadership (QSEAL). www.pptaglobal.org/program/qseal.aspx. Accessed February 8, 2012.
24. Pisani G, Marino F, Cristiano K, Bisso GM, Mele C, Luciani F, Wirz M, Gentili G, External Quality Assessment Participants. (2008) External quality assessment for the detection of HCV RNA, HIV RNA and HBV DNA in plasma by nucleic acid amplification technology: a novel approach. Vox Sang, 95, 8-12.
25. United States Food and Drug Administration Guidance for Industry Use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components (including source plasma and source leukocytes) to adequately and appropriately reduce the risk of transmission of HIV-1 and HCV. www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074934.htm. Accessed February 9, 2011.
26. Zerlauth G. (1999) Assessment of validation studies from a fractionators's point of view. Biologicals, 27, 295-301.
27. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S. (2000) Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification. Testing of Blood Donors, 40, 143-159.
28. Flanagan P, Snape T. (1998) Nucleic acid technology (NAT) testing and the transfusion service: a rationale for the implementation of minipool testing. Transfus Med, 8, 9-13.
29. Burckhardt JJ. (1999). Assessment of needs for plasma for fractionation in Europe. Biologicals, 27, 337-341.
30. Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, Funk MB. (2009) Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion, 49, 1850-1858.
31. Farrugia A. (2004). Plasma for fractionation: safety and quality issues. Haemophilia, 10, 334-340.
32. Nübling CM, Unkelbach U, Chudy M, Seitz R. (2008) Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Transfusion, 48, 822-826.
33. Roth WK, Seifried E. (2001) Yield and future issues of nucleic acid testing. Transfus Clin Biol, 8, 282-284.
34. Guide to the preparation, use and quality assurance of blood components (16th Edition) -recommendation R (95) 15 (2011) Standards for selection of donors. Directorate for the quality of medicines and healthcare, Strasbourg, France. pp. 199-212.
35. Roth WK. (2010) Quarantine plasma: quo vadis. Transfus Med Hemother, 37, 118-122.
36. Guide to the preparation, use and quality assurance of blood components (16th Edition) -recommendation R (95) 15 (2011) Principles of heamovigilance. Directorate for the quality of medicines and healthcare, Strasbourg, France. pp. 175-185.
37. United States Food and Drug Administration. (2007) Current good manufacturing practice for blood and blood components: notification of consignees and tyransfusion recipients receiving blood and blood components at increased risk for transmitting HCV infection ("lookback"). Final rule. Fed Reg, 72, 48765-48801.
38. United States Food and Drug Administration, Code of Federal Regulations Title 21 Part 210 Food and Drugs. Current good manufacturing practice in manufacturing, processing, packing, or general holding of drugs: general www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210. Accessed 8 February 2012
39. United States Food and Drug Administration, Code of Federal Regulations Title 21 Part 211 Food and Drugs. Current good manufacturing practice for finished pharmaceuticals. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211. Accessed February 8, 2012.
40. Motschman TL, Jett BW, Wilkinson SL. (2008) Quality systems; theory and practice. In: Technical manual, 16th edition (Roback JD, Combs MR, Grossman BJ, Hillyer CD, eds.). American Association of Blood Banks, Maryland, USA, pp. 1-39.
41. United States Food and Drug Administration. (2009) Guidance for industry: Q10 pharmaceutical quality system. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073517.pdf.
42. World Health Organization. Ensuring the Quality and Safety of Plasma Derived Medicinal Products. World Health Organisation, Quality and Safety of Blood Products and Related Substances, Department of Essential Health Technologies, Geneva, Switzerland. www.who.int/bloodproducts/publications/en/Infosheet_plasma_derived.pdf. Accessed February 9, 2012.
43. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). www.ich.org. Accessed February 9, 2012.
44. UK Blood Transfusion & Tissue Transplantation Services. (2005) Guidelines for the blood transfusion services in the UK 7th edition. www.transfusionguidelines.org.uk/Index.aspx?Publication=RB&Section=25&pageid=759. Accessed February 9, 2012.
45. Australian Red Cross Blood Service. (2009) Blood component information. Australian Red Cross Blood Service (ARCBS), Melbourne, Australia. www.transfusion.com.au/sites/default/files/BCI%202009.pdf. Accessed February 9, 2012.